Sanofi and Innate Pharma expand collaboration for natural killer cell therapeutics in oncology
By, Admin1 min read
Share
Sanofi and Innate Pharma SA announced today an expansion of their collaboration, with Sanofi licensing a natural killer (NK) cell engager program targeting B7H3 from Innate
Found this useful? Share it with your team.
Newsletter
Stay ahead with Clival insights
Subscribe to get the latest updates, data releases and industry information — straight to your inbox.
